DOCSLIB.ORG

Discovery of a Selective, State-Independent Inhibitor of Nav1.7 by Modification of Guanidinium Toxins

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Discovery of a Selective, State-Independent Inhibitor of Nav1.7 by Modification of Guanidinium Toxins bioRxiv preprint doi: https://doi.org/10.1101/869206; this version posted December 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Discovery of a Selective, State-Independent Inhibitor of NaV1.7 by Modification of Guanidinium Toxins Authors: Pajouhesh H1, Beckley JT2, Delwig A1, Hajare HS3, Luu G1, Monteleone D1, Zhou X1, 5 Ligutti J4, Amagasu S4, Moyer BD4, Yeomans D5, Du Bois J4, Mulcahy JV1* Affiliations: 1SiteOne Therapeutics, South San Francisco, CA 94080 2SiteOne Therapeutics, Bozeman, MT 59718 3Department of Chemistry, Stanford University, Stanford, CA 94305 10 4Neuroscience Department, Amgen Research, Thousand Oaks, CA 91320 5Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, CA 94305 *Correspondence to: [email protected] 15 Abstract The voltage-gated sodium channel isoform NaV1.7 is highly expressed in small diameter dorsal root ganglion neurons and is obligatory for nociceptive signal transmission. Genetic gain- of-function and loss-of-function NaV1.7 mutations have been identified in select individuals, and 20 are associated with episodic extreme pain disorders and insensitivity to pain, respectively. These findings implicate NaV1.7 as a key pharmacotherapeutic target for the treatment of pain. While several small molecules targeting NaV1.7 have been advanced to clinical development, no NaV1.7- selective compound has shown convincing efficacy in clinical pain applications. Here we describe the discovery and characterization of ST-2262, a NaV1.7 inhibitor that blocks the extracellular 25 vestibule of the channel with an IC50 of 72 nM and greater than 200-fold selectivity over off-target sodium channel isoforms, NaV1.1–1.6 and NaV1.8. In contrast to other NaV1.7 inhibitors that preferentially inhibit the inactivated state of the channel, ST-2262 is equipotent against resting and inactivated protein conformers. In a non-human primate model, animals treated with ST-2262 exhibit markedly reduced sensitivity to noxious heat. These findings establish the extracellular 30 vestibule of the sodium channel as a viable receptor site for selective ligand design and provide insight into the pharmacology of state-independent inhibition of NaV1.7. Significance Statement Pain is among the most common reasons for seeking medical care, yet many frequently 35 prescribed drugs, particularly the opioids, cause problematic side effects and carry a risk of addiction. Voltage-gated sodium ion channels (NaVs) have emerged as promising targets for the development of non-opioid pain medicines. NaVs are involved in the propagation of electrical signals along neurons throughout the body. Humans born without a functional copy of one sodium channel subtype, NaV1.7, are unable to experience most types of pain. In the present work, we 40 disclose the discovery and characterization of a selective inhibitor of NaV1.7 that reduces sensitivity to a painful thermal stimulus in non-human primates. Findings from this work may help guide the development of novel, non-addictive drug candidates as alternatives to opioids. 1 bioRxiv preprint doi: https://doi.org/10.1101/869206; this version posted December 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Introduction + The voltage-gated Na ion channel (NaV) isoform 1.7 has emerged as a high-interest target for the discovery of non-opioid pain therapeutics based on its preferential expression in small diameter peripheral sensory neurons and compelling Validation from human genetics.(1) NaV1.7 5 loss-of-function mutations result in whole-body insensitivity to pain; conversely, gain-of-function variants are associated with episodic extreme pain disorders and small fiber neuropathies.(2–5) Discovery of selective inhibitors of NaV1.7 has been challenging due to the structural conservation of off-target NaV isoforms (NaV1.1–1.6, NaV1.8 and NaV1.9), inhibition of which is likely to result in safety liabilities.(6–8) 10 NaVs are integral membrane proteins expressed in excitable cells that comprise a ~260 kD pore-forming a-subunit and two accessory b-subunits (Figure 1).(9) The central pore of the a- subunit is encircled by four voltage-sensing domains (VSD I–IV). Channel gating occurs through protein conformational changes in response to membrane depolarization. At least nine discrete binding sites on the NaV a-subunit have been identified for peptides and small molecules that 15 influence ion conductance.(10) The large majority of molecules that engage NaVs bind preferentially to a specific conformational state of the channel and show use-dependent activity. Clinical NaV inhibitors (e.g., bupivacaine, lidocaine, carbamazepine) are both state- and frequency- dependent agents that lodge in the intracellular pore of the a-subunit, a site that is highly conserved between isoforms. These drugs rely on local administration or frequency dependent inhibition to 20 achieve a margin between the desired pharmacodynamic effect and dose-limiting side effects. Investigational NaV inhibitors, such as peptide toxins isolated from venomous species, interact with VSDs, trapping the S4 helix in either an activated or deactivated conformation.(11, 12) Similarly, a class of small molecule aryl and acyl sulfonamide compounds bind to the activated conformation of VSD IV (Figure 1b).(13–16) By contrast, cationic guanidinium toxins and peptide 25 cone snail toxins inhibit ion conduction by sterically occluding the extracellular vestibule of the channel pore (Site 1). The former are a unique collection of natural products exemplified by saxitoxin and tetrodotoxin – high affinity, state independent blockers against six of nine NaV subtypes (Figure 1c).(17) N O O N A. B. O O S S CF S Cl Cl S O O O STX 3 N N N H S (extracellular H N N O O F H vestibule) H3CH2C CN H N O F N 2 N N NH GX-936 GX-936 PF-05089771 GDC-0276 (VSD IV) Genentech/Xenon Pfizer Genentech/Xenon hNaV1.7 IC50 0.001 µM hNaV1.7 IC50 0.011 µM hNaV1.7 IC50 0.0004 µM hNaV1.2 IC50 0.11 µM hNaV1.1 IC50 0.011 µM hNaV1.5 IC50 25 µM hNaV1.2 IC50 0.020 µM hNaV1.6 IC50 0.16 µM hNaV1.5 IC50 0.049 µM O OH HO O C. N HO NH2 O NH2 N NH O O O HO OH NH2 – O3 SO N N H HOHN HO OH HO NH HN NH H OH HOHN N O N OH H2N NH2 H2N O STX TTX ZTX (+)-saxitoxin (–)-tetrodotoxin (–)-zetekitoxin AB 30 Figure 1. (a) Cryo-EM structure of STX bound to human NaV1.7-b1-b2 complex (PDB: 6j8g) with GX-936 positioned approximately based on PDB: 5ek0. (b) RepresentatiVe NaV1.7 inhibitors that bind VSD IV. (c) Natural NaV inhibitors that bind to the extracellular vestibule.(18–21) In the pursuit of isoform-selective inhibitors of NaV1.7, two binding sites, the cystine knot 35 toxin site at VSD II and the sulfonamide site at VSD IV, have been heavily interrogated. Certain 2 bioRxiv preprint doi: https://doi.org/10.1101/869206; this version posted December 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. cystine knot toxins that engage VSD II such as HwTx-IV, Pn3a and ProTx-II exhibit 6–1000x selectivity for NaV1.7 over other channel isoforms. Potency and selectivity for this target have been improved with synthetic toxin derivatives.(22–26) Among small, Lipinski-type molecules, only the aryl and acyl sulfonamides pioneered by Icagen/Pfizer and subsequently investigated by 5 Amgen, Chromocell, Genentech/Xenon, Merck and others have shown evidence of significant NaV1.7 isoform selectivity.(16, 7) Within the sulfonamide series, selectivity levels are >1000x over certain off-target isoforms including the cardiac isoform, NaV1.5, but generally 10–50x against NaV1.2 and NaV1.6. Many but not all sulfonamide NaV1.7 inhibitors suffer from undesirable pharmaceutical properties, including high plasma protein binding (e.g. >99.8%), 10 cytochrome p450 inhibition, in vitro hepatotoxicity and high unbound clearance,(27, 28) which have hindered clinical development. Although a number of candidates have been advanced to human testing, one compound has been discontinued after a Phase 2 study likely due to limited efficacy (PF-05089771); others have been discontinued after Phase 1 trials for reasons that may be related to safety liabilities such as elevated expression of liver transaminases and hypotension 15 (GDC-0276).(29, 30) Electrophysiology studies with naturally occurring Site 1 ligands against different wild- type and mutant NaV isoforms have identified the extracellular vestibule of NaV1.7 as a promising locus for selective inhibitor design.(31–33) The outer mouth of the channel is formed from residues that link the S5–S6 helices (referred to as pore loops) from each of the four domains. The domain 20 III pore loop of human NaV1.7 contains a sequence variation, 1398T/1399I, that is not present in other human NaV subtypes (which contain MD at equivalent position, Suppl Table 1).(31) Comparison of the amino acid sequence of the domain III pore loop across species indicates that this variation is unique to primates. The half maximal inhibitory concentration (IC50) value for saxitoxin (STX) is markedly altered (250-fold change) depending on the presence or absence of 25 the 1398T/1399I variant. Against rNaV1.4, the IC50 of STX is 2.8 ± 0.1 nM compared to hNaV1.7 for which the IC50 = 702 ± 53 nM.(31) Introduction of the alternative domain III pore loop sequence by mutagenesis restores potency (hNaV1.7 T1398M/I1399D IC50 = 2.3 ± 0.2 nM).
Load more

Recommended publications
  • Tetrodotoxin
    Niharika Mandal et al. / Journal of Pharmacy Research 2012,5(7),3567-3570 Review Article Available online through ISSN: 0974-6943 http://jprsolutions.info Tetrodotoxin: An intriguing molecule Niharika Mandal*, Samanta Sekhar Khora, Kanagaraj Mohanapriya, and Soumya Jal School of Biosciences and Technology, VIT University, Vellore-632013 Tamil Nadu, India Received on:07-04-2012; Revised on: 12-05-2012; Accepted on:16-06-2012 ABSTRACT Tetrodotoxin (TTX) is one of the most potent neurotoxin of biological origin. It was first isolated from puffer fish and it has been discovered in various arrays of organism since then. Its origin is still unclear though some reports indicate towards microbial origin. TTX selectively blocks the sodium channel, inhibiting action potential thereby, leading to respiratory paralysis. TTX toxicity is mainly caused due to consumption of puffer fish. No Known antidote for TTX exists. Treatment is symptomatic. The present review is therefore, an effort to give an idea about the distribution, origin, structure, pharmacol- ogy, toxicity, symptoms, treatment, resistance and application of TTX. Key words: Tetrodotoxin, Neurotoxin, Puffer fish. INTRODUCTION One of the most intriguing biotoxins isolated and described in the twentieth cantly more toxic than TTX. Palytoxin and maitotoxin have potencies nearly century is the neurotoxin, Tetrodotoxin (TTX, CAS Number [4368-28-9]). 100 times that of TTX and Saxitoxin, and all four toxins are unusual in being A neurotoxin is a toxin that acts specifically on neurons usually by interact- non-proteins. Interestingly, there is also some evidence for a bacterial bio- ing with membrane proteins and ion channels mostly resulting in paralysis.
    [Show full text]
  • Examples of Successful Protein Expression with SUMO Reference Protein Type Family Kda System (Pubmed ID)
    Examples of Successful Protein Expression with SUMO Reference Protein Type Family kDa System (PubMed ID) 23 (FGF23), human Growth factor FGF superfamily ~26 E. coli 22249723 SARS coronavirus (SARS-CoV) membrane 3C-like (3CL) protease Viral membrane protein protein 33.8 E. coli 16211506 5′nucleotidase-related apyrase (5′Nuc) Saliva protein (apyrase) 5′nucleotidase-related proteins 65 E. coli 20351782 Acetyl-CoA carboxylase 1 (ACC1) Cytosolic enzyme Family of five biotin-dependent carboxylases ~7 E. coli 22123817 Acetyl-CoA carboxylase 2 (ACC2) BCCP domain Cytosolic enzyme Family of five biotin-dependent carboxylases ~7 E. coli 22123817 Actinohivin (AH) Lectin Anti-HIV lectin of CBM family 13 12.5 E. coli DTIC Allium sativum leaf agglutinin (ASAL) Sugar-binding protein Mannose-binding lectins 25 E. coli 20100526 Extracellular matrix Anosmin protein Marix protein 100 Mammalian 22898776 Antibacterial peptide CM4 (ABP-CM4) Antibacterial peptide Cecropin family of antimicrobial peptides 3.8 E. coli 19582446 peptide from centipede venoms of Scolopendra Antimicrobial peptide scolopin 1 (AMP-scolopin 1) small cationic peptide subspinipes mutilans 2.6 E. coli 24145284 Antitumor-analgesic Antitumor-analgesic peptide (AGAP) peptide Multifunction scorpion peptide 7 E. coli 20945481 Anti-VEGF165 single-chain variable fragment (scFv) Antibody Small antibody-engineered antibody 30 E. coli 18795288 APRIL TNF receptor ligand tumor necrosis factor (TNF) ligand 16 E. coli 24412409 APRIL (A proliferation-inducing ligand, also named TALL- Type II transmembrane 2, TRDL-1 and TNFSF-13a) protein Tumor necrosis factor (TNF) family 27.51 E. coli 22387304 Aprotinin/Basic pancreatic trypsin inhibitor (BPTI) Inhibitor Kunitz-type inhibitor 6.5 E.
    [Show full text]
  • Interactions of Insecticidal Spider Peptide Neurotoxins with Insect Voltage- and Neurotransmitter-Gated Ion Channels
    Interactions of insecticidal spider peptide neurotoxins with insect voltage- and neurotransmitter-gated ion channels (Molecular representation of - HXTX-Hv1c including key binding residues, adapted from Gunning et al, 2008) PhD Thesis Monique J. Windley UTS 2012 CERTIFICATE OF AUTHORSHIP/ORIGINALITY I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as fully acknowledged within the text. I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis. Monique J. Windley 2012 ii ACKNOWLEDGEMENTS There are many people who I would like to thank for contributions made towards the completion of this thesis. Firstly, I would like to thank my supervisor Prof. Graham Nicholson for his guidance and persistence throughout this project. I would like to acknowledge his invaluable advice, encouragement and his neverending determination to find a solution to any problem. He has been a valuable mentor and has contributed immensely to the success of this project. Next I would like to thank everyone at UTS who assisted in the advancement of this research. Firstly, I would like to acknowledge Phil Laurance for his assistance in the repair and modification of laboratory equipment. To all the laboratory and technical staff, particulary Harry Simpson and Stan Yiu for the restoration and sourcing of equipment - thankyou. I would like to thank Dr Mike Johnson for his continual assistance, advice and cheerful disposition.
    [Show full text]
  • Suppression of Potassium Conductance by Droperidol Has
    Anesthesiology 2001; 94:280–9 © 2001 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Suppression of Potassium Conductance by Droperidol Has Influence on Excitability of Spinal Sensory Neurons Andrea Olschewski, Dr.med.,* Gunter Hempelmann, Prof., Dr.med., Dr.h.c.,† Werner Vogel, Prof., Dr.rer.nat.,‡ Boris V. Safronov, P.D., Ph.D.§ Background: During spinal and epidural anesthesia with opi- Naϩ conductance.5–8 The sensitivity of different compo- oids, droperidol is added to prevent nausea and vomiting. The nents of Naϩ current to droperidol has further been mechanisms of its action on spinal sensory neurons are not studied in spinal dorsal horn neurons9 by means of the well understood. It was previously shown that droperidol se- 10,11 lectively blocks a fast component of the Na؉ current. The au- “entire soma isolation” (ESI) method. The ESI Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/94/2/280/403011/0000542-200102000-00018.pdf by guest on 25 September 2021 thors studied the action of droperidol on voltage-gated K؉ chan- method allowed a visual identification of the sensory nels and its effect on membrane excitability in spinal dorsal neurons within the spinal cord slice and further pharma- horn neurons of the rat. cologic study of ionic channels in their isolated somata Methods: Using a combination of the patch-clamp technique and the “entire soma isolation” method, the action of droperi- under conditions in which diffusion of the drug mole- -dol on fast-inactivating A-type and delayed-rectifier K؉ chan- cules is not impeded by the connective tissue surround nels was investigated.
    [Show full text]
  • Biological Toxins Fact Sheet
    Work with FACT SHEET Biological Toxins The University of Utah Institutional Biosafety Committee (IBC) reviews registrations for work with, possession of, use of, and transfer of acute biological toxins (mammalian LD50 <100 µg/kg body weight) or toxins that fall under the Federal Select Agent Guidelines, as well as the organisms, both natural and recombinant, which produce these toxins Toxins Requiring IBC Registration Laboratory Practices Guidelines for working with biological toxins can be found The following toxins require registration with the IBC. The list in Appendix I of the Biosafety in Microbiological and is not comprehensive. Any toxin with an LD50 greater than 100 µg/kg body weight, or on the select agent list requires Biomedical Laboratories registration. Principal investigators should confirm whether or (http://www.cdc.gov/biosafety/publications/bmbl5/i not the toxins they propose to work with require IBC ndex.htm). These are summarized below. registration by contacting the OEHS Biosafety Officer at [email protected] or 801-581-6590. Routine operations with dilute toxin solutions are Abrin conducted using Biosafety Level 2 (BSL2) practices and Aflatoxin these must be detailed in the IBC protocol and will be Bacillus anthracis edema factor verified during the inspection by OEHS staff prior to IBC Bacillus anthracis lethal toxin Botulinum neurotoxins approval. BSL2 Inspection checklists can be found here Brevetoxin (http://oehs.utah.edu/research-safety/biosafety/ Cholera toxin biosafety-laboratory-audits). All personnel working with Clostridium difficile toxin biological toxins or accessing a toxin laboratory must be Clostridium perfringens toxins Conotoxins trained in the theory and practice of the toxins to be used, Dendrotoxin (DTX) with special emphasis on the nature of the hazards Diacetoxyscirpenol (DAS) associated with laboratory operations and should be Diphtheria toxin familiar with the signs and symptoms of toxin exposure.
    [Show full text]
  • Animal Venom Derived Toxins Are Novel Analgesics for Treatment Of
    Short Communication iMedPub Journals 2018 www.imedpub.com Journal of Molecular Sciences Vol.2 No.1:6 Animal Venom Derived Toxins are Novel Upadhyay RK* Analgesics for Treatment of Arthritis Department of Zoology, DDU Gorakhpur University, Gorakhpur, UP, India Abstract *Corresponding authors: Ravi Kant Upadhyay Present review article explains use of animal venom derived toxins as analgesics of the treatment of chronic pain and inflammation occurs in arthritis. It is a [email protected] progressive degenerative joint disease that put major impact on joint function and quality of life. Patients face prolonged inappropriate inflammatory responses and bone erosion. Longer persistent chronic pain is a complex and debilitating Department of Zoology, DDU Gorakhpur condition associated with a large personal, mental, physical and socioeconomic University, Gorakhpur, UttarPradesh, India. burden. However, for mitigation of inflammation and sever pain in joints synthetic analgesics are used to provide quick relief from pain but they impose many long Tel: 9838448495 term side effects. Venom toxins showed high affinity to voltage gated channels, and pain receptors. These are strong inhibitors of ion channels which enable them as potential therapeutic agents for the treatment of pain. Present article Citation: Upadhyay RK (2018) Animal Venom emphasizes development of a new class of analgesic agents in form of venom Derived Toxins are Novel Analgesics for derived toxins for the treatment of arthritis. Treatment of Arthritis. J Mol Sci. Vol.2 No.1:6 Keywords: Analgesics; Venom toxins; Ion channels; Channel inhibitors; Pain; Inflammation Received: February 04, 2018; Accepted: March 12, 2018; Published: March 19, 2018 Introduction such as the back, spine, and pelvis.
    [Show full text]
  • A Functional Nav1.7-Navab Chimera with a Reconstituted High-Affinity Protx-II Binding Site S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/06/23/mol.117.108712.DC1 1521-0111/92/3/310–317$25.00 https://doi.org/10.1124/mol.117.108712 MOLECULAR PHARMACOLOGY Mol Pharmacol 92:310–317, September 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics A Functional NaV1.7-NaVAb Chimera with a Reconstituted High-Affinity ProTx-II Binding Site s Ramkumar Rajamani, Sophie Wu, Iyoncy Rodrigo, Mian Gao, Simon Low, Lisa Megson, David Wensel, Rick L. Pieschl, Debra J. Post-Munson, John Watson, David R. Langley, Michael K. Ahlijanian, Linda J. Bristow, and James Herrington Molecular Discovery Technologies, Wallingford, Connecticut, Princeton, New Jersey, and Waltham, Massachusetts (R.R., S.W., I.R., M.G., S.L., L.M., D.W., D.R.L.); Discovery Biology (R.L.P., D.J.P.-M., M.K.A., L.J.B., J.H.) and Lead Discovery and Optimization (J.W.), Bristol-Myers Squibb Company, Wallingford, Connecticut Downloaded from Received March 6, 2017; accepted June 14, 2017 ABSTRACT The NaV1.7 voltage-gated sodium channel is implicated in part of the voltage sensor domain 2 (VSD2) of NaV1.7. Importantly, human pain perception by genetics. Rare gain of function this chimera, DII S1–S4, forms functional sodium channels and is molpharm.aspetjournals.org mutations in NaV1.7 lead to spontaneous pain in humans whereas potently inhibited by the NaV1.7 VSD2 targeted peptide toxin loss of function mutations results in congenital insensitivity to pain. ProTx-II. Further, we show by [125I]ProTx-II binding and surface Hence, agents that specifically modulate the function of NaV1.7 plasmon resonance that the purified DII S1–S4 protein retains high have the potential to yield novel therapeutics to treat pain.
    [Show full text]
  • Saxitoxin and ,U-Conotoxins (Brain/Electric Organ/Heart/Tetrodotoxin) EDWARD MOCZYDLOWSKI*, BALDOMERO M
    Proc. Nati. Acad. Sci. USA Vol. 83, pp. 5321-5325, July 1986 Neurobiology Discrimination of muscle and neuronal Na-channel subtypes by binding competition between [3H]saxitoxin and ,u-conotoxins (brain/electric organ/heart/tetrodotoxin) EDWARD MOCZYDLOWSKI*, BALDOMERO M. OLIVERAt, WILLIAM R. GRAYt, AND GARY R. STRICHARTZt *Department of Physiology and Biophysics, University of Cincinnati College of Medicine, 231 Bethesda Avenue, Cincinnati, OH 45267-0576; tDepartment of Biology, University of Utah, Salt Lake City, UT 84112; and tAnesthesia Research Laboratories and the Department of Pharmacology, Harvard Medical School, Boston, MA 02115 Communicated by Norman Davidson, March 17, 1986 ABSTRACT The effect oftwo pL-conotoxin peptides on the 22 amino acids with amidated carboxyl termini (18). One of specific binding of [3H]saxitoxin was examined in isolated these toxins, GIIIA, has recently been shown to block muscle plasma membranes of various excitable tissues. pt-Conotoxins action potentials (18) and macroscopic Na current in a GITIA and GIHIB inhibit [3H]saxitoxin binding inlEkctrophorus voltage-clamped frog muscle fiber (19). At the single channel electric organ membranes with similar Kds of %50 x 10-9 M level, the kinetics of GIIIA block have been shown to in a manner consistent with direct competition for a common conform to a single-site binding model (Kd, 110 x 10-9 M at binding site. GITIA and GIIIB similarly compete with the 0 mV), from analysis of the statistics of discrete blocking majority (80-95%) of [3Hlsaxitoxin binding sites in rat skeletal events induced in batrachotoxin-activated Na channels from muscle with Kds of -25 and "140 x 10-9 M, respectively.
    [Show full text]
  • Slow Inactivation in Voltage Gated Potassium Channels Is Insensitive to the Binding of Pore Occluding Peptide Toxins
    Biophysical Journal Volume 89 August 2005 1009–1019 1009 Slow Inactivation in Voltage Gated Potassium Channels Is Insensitive to the Binding of Pore Occluding Peptide Toxins Carolina Oliva, Vivian Gonza´lez, and David Naranjo Centro de Neurociencias de Valparaı´so, Facultad de Ciencias, Universidad de Valparaı´so, Valparaı´so, Chile ABSTRACT Voltage gated potassium channels open and inactivate in response to changes of the voltage across the membrane. After removal of the fast N-type inactivation, voltage gated Shaker K-channels (Shaker-IR) are still able to inactivate through a poorly understood closure of the ion conduction pore. This, usually slower, inactivation shares with binding of pore occluding peptide toxin two important features: i), both are sensitive to the occupancy of the pore by permeant ions or tetraethylammonium, and ii), both are critically affected by point mutations in the external vestibule. Thus, mutual interference between these two processes is expected. To explore the extent of the conformational change involved in Shaker slow inactivation, we estimated the energetic impact of such interference. We used kÿconotoxin-PVIIA (kÿPVIIA) and charybdotoxin (CTX) peptides that occlude the pore of Shaker K-channels with a simple 1:1 stoichiometry and with kinetics 100-fold faster than that of slow inactivation. Because inactivation appears functionally different between outside-out patches and whole oocytes, we also compared the toxin effect on inactivation with these two techniques. Surprisingly, the rate of macroscopic inactivation and the rate of recovery, regardless of the technique used, were toxin insensitive. We also found that the fraction of inactivated channels at equilibrium remained unchanged at saturating kÿPVIIA.
    [Show full text]
  • Pain Research Product Guide | Edition 2
    Pain Research Product Guide | Edition 2 Chili plant Capsicum annuum A source of Capsaicin Contents by Research Area: • Nociception • Ion Channels • G-Protein-Coupled Receptors • Intracellular Signaling Tocris Product Guide Series Pain Research Contents Page Nociception 3 Ion Channels 4 G-Protein-Coupled Receptors 12 Intracellular Signaling 18 List of Acronyms 21 Related Literature 22 Pain Research Products 23 Further Reading 34 Introduction Pain is a major public health problem with studies suggesting one fifth of the general population in both the USA and Europe are affected by long term pain. The International Association for the Study of Pain (IASP) defines pain as ‘an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage’. Management of chronic pain in the clinic has seen only limited progress in recent decades. Treatment of pain has been reliant on, and is still dominated by two classical medications: opioids and non-steroidal anti-inflammatory drugs (NSAIDs). However, side effects such as dependence associated with opioids and gastric ulceration associated with NSAIDs demonstrates the need for new drug targets and novel compounds that will bring in a new era of pain therapeutics. Pain has been classified into three major types: nociceptive pain, inflammatory pain and neuropathic or pathological pain. Nociceptive pain involves the transduction of painful stimuli by peripheral sensory nerve fibers called nociceptors. Neuropathic pain results from damage or disease affecting the sensory system, and inflammatory pain represents the immunological response to injury through inflammatory mediators that contribute to pain. Our latest pain research guide focuses on nociception and the transduction of pain to the spinal cord, examining some of the main classical targets as well as emerging pain targets.
    [Show full text]
  • Evidence That Tetrodotoxin and Saxitoxin Act at a Metal Cation Binding Site in the Sodium Channels of Nerve Membrane (Solubilized Membrane/Receptors/Surface Charge) R
    Proc. Nat. Acad. Sci. USA 71 Vol. 71, No. 10, pp. 3936-3940, October 1974 Evidence That Tetrodotoxin and Saxitoxin Act at a Metal Cation Binding Site in the Sodium Channels of Nerve Membrane (solubilized membrane/receptors/surface charge) R. HENDERSON*, J. M. RITCHIE, AND G. R. STRICHARTZt Departments of Molecular Biophysics and Biochemistry, and of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510 Communicated by Frederic M. Richards, June 17, 1974 ABSTRACT The effects of monovalent, divalent, and STX. These experiments suggest how the toxins exert their trivalent cations on the binding of tetrodotoxin and saxi- toxin to intact nerves and to a preparation of solubilized action, and provide a unifying explanation of how several nerve membranes have been examined. All eight divalent cations affect nerve membrane permeability. and trivalent cations tested, and the monovalent ions MATERIALS AND LiW, Tl+, and H+ appear to compete reversibly with the METHODS toxins for their binding site. The ability of lithium to Tritium-labeled TTX and STX were prepared and purified reduce toxin binding is paralleled by its ability to reduce (3, 5). Olfactory nerves from garfish, obtained from the Gulf tetrodotoxin-sensitive ion fluxes through the nerve mem- brane. We conclude that the toxins act at a metal cation Specimen Co., Florida, were dissected by the method of binding site in the sodium channel and suggest that this Easton (12). A detergent-solubilized extract of the nerves site is the principal coordination site for cations (normally was prepared by the method of Henderson and Wang (4). Na+ ions) as they pass through the membrane during an Binding experiments were also carried out on intact garfish action potential.
    [Show full text]
  • Alcohol Dependence and Withdrawal Impair Serotonergic Regulation Of
    Research Articles: Cellular/Molecular Alcohol dependence and withdrawal impair serotonergic regulation of GABA transmission in the rat central nucleus of the amygdala https://doi.org/10.1523/JNEUROSCI.0733-20.2020 Cite as: J. Neurosci 2020; 10.1523/JNEUROSCI.0733-20.2020 Received: 30 March 2020 Revised: 8 July 2020 Accepted: 14 July 2020 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2020 the authors 1 Alcohol dependence and withdrawal impair serotonergic regulation of GABA 2 transmission in the rat central nucleus of the amygdala 3 Abbreviated title: Alcohol dependence impairs CeA regulation by 5-HT 4 Sophia Khom, Sarah A. Wolfe, Reesha R. Patel, Dean Kirson, David M. Hedges, Florence P. 5 Varodayan, Michal Bajo, and Marisa Roberto$ 6 The Scripps Research Institute, Department of Molecular Medicine, 10550 N. Torrey Pines 7 Road, La Jolla CA 92307 8 $To whom correspondence should be addressed: 9 Dr. Marisa Roberto 10 Department of Molecular Medicine 11 The Scripps Research Institute 12 10550 N. Torrey Pines Road, La Jolla, CA 92037 13 Tel: (858) 784-7262 Fax: (858) 784-7405 14 Email: [email protected] 15 16 Number of pages: 30 17 Number of figures: 7 18 Number of tables: 2 19 Number of words (Abstract): 250 20 Number of words (Introduction): 650 21 Number of words (Discussion): 1500 22 23 The authors declare no conflict of interest.
    [Show full text]